David Frey

David Frey has extensive experience in the biopharmaceutical industry, particularly in the field of cell and viral therapies. David has held various leadership roles in companies such as Atara Biotherapeutics, Opexa Therapeutics, Cellerant Therapeutics, Cell Genesys, and Anergen.

At Atara Biotherapeutics, David served as the VP of Process Sciences, where they established and developed functions and capabilities for T-cell and virus reagent manufacturing platforms. David brought an EBV-specific allogeneic T-cell therapy from an academic phase-1 investigational product to MAA approval, focusing on scalable closed automated production systems.

Prior to that, they were the Senior Director of Manufacturing at Opexa Therapeutics and led the manufacturing department. At Cellerant Therapeutics, they served as the Director of Process Development and led the animal analog manufacturing and process development functions.

David has also worked as a bioprocess consultant for various cell and viral therapy clients, providing strategic and tactical support for product development efforts. Additionally, they have held roles in process development and manufacturing at Cell Genesys and Anergen, where they contributed to the development and manufacturing of virus and cell therapy products.

Overall, David Frey has a strong background in process development, manufacturing, and regulatory compliance in the biopharmaceutical industry, particularly in the field of cell and viral therapies.

David Frey attended the University of California, Berkeley from 1990 to 1993, where they earned a Bachelor of Science degree in Chemical Engineering.